Blueprint Medicines Corp Stock
Blueprint Medicines Corp Stock
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Blueprint Medicines Corp stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Blueprint Medicines Corp in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Blueprint Medicines Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | - | - | - | - | - | - | - |
| Ironwood Pharmaceuticals | 0.000% | 11.047% | 28.188% | 5.525% | 43.609% | -64.003% | -58.251% |
| Novocure Ltd | 0.380% | -7.870% | 6.809% | -53.443% | 3.794% | -86.440% | -91.518% |
| Iovance Biotherapeutics Inc. | 4.280% | -3.379% | 6.722% | -63.598% | -14.397% | -65.579% | -95.196% |
News
Why Ford's Deal With Amazon Is Bigger Than You Think
Ford Motor Company (NYSE: F) has made a groundbreaking move in automotive retail, announcing a partnership to sell its certified pre-owned (CPO) vehicles directly on Amazon (NASDAQ: AMZN).
This
Time to Take Notice: PEGA’s GenAI Blueprint Delivers Huge Q3 Beat
On a day that saw a handful of highly impressive earnings reports, tech stock Pegasystems (NASDAQ: PEGA) more than held its own. Shares blasted up by 15% on Oct. 22 as the market digested the
PEGA Surges 14%: There's Still Time to Ride This GenAI Innovator
For the second quarter in a row, artificial intelligence (AI) tech stock Pegasystems (NASDAQ: PEGA) crushed expectations.
Shares soared 14% on July 22 as the company eclipsed Wall Street